Core Viewpoint - The company Aihuilong (688575.SH) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, which has led to significant discrepancies between analyst predictions and actual financial performance [1][3][9]. Group 1: Company Performance and Analyst Predictions - Aihuilong's stock price showed minimal fluctuation after the announcement of the investigation, with a drop of less than 3% the following day, despite prior volatility [1][3]. - Prior to the investigation, Aihuilong's performance was unexpectedly poor, particularly noted by analyst Zhou Chaoze from Founder Securities, who had issued two reports recommending the stock [3][8]. - In August, a report predicted a recovery in Aihuilong's performance, estimating net profits of 126 million yuan and 297 million yuan for 2025 and 2026, respectively [3][9]. - The company's Q3 report revealed a net profit of less than 55 million yuan, significantly lower than the previous estimates, indicating a need for over 70 million yuan in Q4 to meet earlier forecasts [3][9]. - In November, despite the disappointing Q3 results, Zhou maintained a positive outlook, revising the profit estimates slightly down to 119 million yuan and 291 million yuan for 2025 and 2026 [4][9]. - Aihuilong later issued a profit warning in January, forecasting a net profit of only 20 million to 30 million yuan for 2025, a decrease of 90.05% to 93.37% compared to the previous year [5][10]. - Ultimately, Aihuilong not only failed to achieve the projected Q4 profit but also incurred a loss of over 30 million yuan, resulting in actual profits being only a quarter of the analyst's earlier estimates [6][10].

Recent Events - Yahui Long (688575) announced on February 6, 2026, that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to misleading statements in a brain-computer interface strategic cooperation announcement made on January 7, 2026, which initially claimed the partner had invasive technology but later corrected it to only non-invasive technology [2] - Tian Sheng New Materials (300169) was also investigated on the same day, potentially involving undisclosed related party transactions for the year 2023. The company is at a critical period of control change, with the investigation results pending final determination by the CSRC [2] Performance and Operations - Yahui Long reported a 72.36% year-on-year decline in net profit for the first three quarters of 2025, indicating that the brain-computer interface cooperative product is still in the early stages of development, which carries uncertainties [3] - Tian Sheng New Materials has incurred losses for six consecutive years and has negative net assets, with the investigation potentially affecting the process of control change [3]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. (stock code: 688575) is under investigation by the China Securities Regulatory Commission (CSRC) for misleading statements in information disclosure [1][4]. Company Overview - Yahui Long was established in 2008 and is headquartered in Shenzhen, focusing on the in vitro diagnostics (IVD) sector [4][5]. - The company specializes in the research, production, and sales of chemiluminescent immunodiagnostic reagents, biochemical diagnostic reagents, and related instruments, holding a significant market share in autoimmune disease detection [4][5]. Investigation Details - The investigation stems from a voluntary disclosure made by Yahui Long on January 6, 2026, regarding a strategic cooperation agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [5][6]. - Following the announcement, Yahui Long's stock price rose by 6.52% on January 7, with trading volume increasing by 299% compared to the previous day [2][5]. Regulatory Response - The Shanghai Stock Exchange issued an inquiry letter to Yahui Long, requesting verification of the technology path, product status, and research progress of Brain Machine Star Chain [2][6]. - Yahui Long later acknowledged that Brain Machine Star Chain is currently focused only on non-invasive technology and has no invasive technology layout, with some products still in early research or preclinical stages [2][5]. Compliance Issues - The Shanghai Stock Exchange issued a regulatory warning to Yahui Long's then Secretary of the Board, Wang Mingyang, for inconsistent disclosures and insufficient risk warnings [6]. - The CSRC's investigation aims to ensure the healthy development of the market following the company's failure to adequately disclose cooperation feasibility and uncertainties [6].

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. (stock code: 688575) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation for suspected violations of information disclosure laws [1] Group 1: Investigation Details - The CSRC has decided to initiate a formal investigation against the company due to alleged violations of the Securities Law of the People's Republic of China and the Administrative Penalty Law [1] - The company will actively cooperate with the CSRC during the investigation and will adhere to regulatory disclosure obligations [1] - As of the announcement date, the company has not received a final conclusion from the CSRC regarding the investigation [1] Group 2: Investor Compensation - Investors who purchased Yahui Long shares between the listing date and February 7, 2026, and either held or sold the shares after February 8, 2026, may be eligible for compensation [2] - The initial compensation conditions are subject to confirmation by the court's effective judgment [2] - Required documentation for compensation includes original transaction statements, copies of investor identification, and confirmation of securities account information from the brokerage [3]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. (stock code: 688575) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, as indicated in the notice received on February 6, 2026 [1][4]. Group 1: Investigation Details - The CSRC has issued a formal notice of investigation (No. 00720262) against Yahui Long for alleged violations of the Securities Law and the Administrative Penalty Law of the People's Republic of China [1][4]. - Yahui Long has committed to cooperating with the CSRC during the investigation and will adhere to regulatory disclosure requirements [1][4]. Group 2: Investor Compensation - Affected investors who purchased Yahui Long shares before February 7, 2026, and sold or continued to hold them after February 8, 2026, may be eligible for compensation [2][4]. - The preliminary compensation criteria include investors who bought shares between the company's listing and February 7, 2026, and held or sold them after February 8, 2026 [5]. Group 3: Required Documentation for Claims - Investors must prepare original transaction statements for Yahui Long shares, stamped by the brokerage, showing all trading records from the first purchase to the date of sale or the print date [5][6]. - Additional required documents include copies of the investor's ID, and a confirmation of the securities account information from the brokerage [6].

Core Viewpoint - The company Aihuilong (688575.SH) is under investigation by the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure laws, which has led to a decline in its stock price and raised concerns about its strategic partnership with Brain Machine Star Chain Technology Co., Ltd. [1][5] Group 1: Investigation and Stock Impact - On February 6, Aihuilong received a notice from the CSRC regarding an investigation due to misleading statements related to a strategic cooperation framework agreement signed with Brain Machine Star Chain [1][5] - Following the announcement of the partnership, Aihuilong's stock price fell by 2.98% to 14.02 yuan per share, with a significant increase in trading volume [1][3] - The Shanghai Stock Exchange issued a regulatory warning to Aihuilong, emphasizing the need for accurate and complete information disclosure, especially given the market's heightened interest in brain-machine interface technology [3][4] Group 2: Business Operations and Financial Forecast - Aihuilong's main business involves the research, production, and sales of in vitro diagnostic instruments and related reagents, covering various medical fields [6] - The company expects a significant decline in net profit for 2025, projecting a decrease of approximately 90.05% to 93.37% compared to 2024, with net profit estimated between 20 million to 30 million yuan [6][7] - The decline in profit is attributed to reduced domestic market demand due to industry policies, leading to decreased revenue and gross margin [6][7] Group 3: Strategic Partnership Details - Aihuilong announced a strategic partnership with Brain Machine Star Chain to develop brain-machine interface products, focusing on non-invasive technology [4] - The estimated investment for the collaboration is around 30 million yuan, with Aihuilong's investment not exceeding 15 million yuan [4] - Brain Machine Star Chain, established in September 2025, has a registered capital of 5 million yuan and claims to focus on both non-invasive and invasive brain-machine interface technologies [4]

Core Viewpoint - YHLO (688575.SH) has transitioned from being a "market darling" to a subject of investigation for information disclosure violations within a month, following its announcement to enter the brain-computer interface sector [1][2]. Group 1: Regulatory Issues - YHLO was officially investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which was triggered by its announcement on January 6 regarding a strategic cooperation framework with Brain Machine Star Chain Technology Co., Ltd [1][4]. - The Shanghai Stock Exchange (SSE) had previously issued a warning to YHLO's then Secretary of the Board for discrepancies and incomplete information in its disclosures related to the cooperation announcement [2][3]. Group 2: Financial Performance - YHLO's financial performance is under pressure, with a forecasted net profit attributable to shareholders for 2025 expected to be between 20 million to 30 million yuan, representing a year-on-year decline of 90.05% to 93.37% [1][6]. - The company reported revenues of 39.81 billion yuan in 2022, which dropped to 20.53 billion yuan in 2023, and is projected to further decline to 20.12 billion yuan in 2024 [6]. - The decline in profitability is attributed to reduced market demand, losses from trading financial assets, and the need for asset impairment provisions [7]. Group 3: Market and Product Development - YHLO has been focusing on expanding its product offerings, with its domestic chemiluminescence product menu increasing to 180 items by the end of 2025 [8]. - Despite challenges in the domestic market, YHLO's international marketing business has shown stable growth, with ongoing efforts in regional coverage and local service [7].

Core Viewpoint - The company, specializing in the IVD (in vitro diagnostics) sector, is under investigation by the China Securities Regulatory Commission (CSRC) for alleged misleading disclosures related to a strategic cooperation agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [2][7] Company Overview - The company is engaged in the research, production, sales, and service of IVD products and is recognized as a national high-tech enterprise with numerous intellectual property rights [6][7] - It has received multiple awards, including the Shenzhen Science and Technology Progress Award and the Guangdong Province Patent Award [6] Regulatory Issues - On February 6, 2026, the CSRC issued a notice of investigation due to potential violations of information disclosure laws concerning the strategic cooperation agreement with Brain Machine Star Chain [2][7] - The initial announcement on January 6, 2026, claimed collaboration in product development and market promotion, but subsequent disclosures clarified that the products were still in early research or preclinical stages [2][7] Market Reaction - The "brain-machine interface" concept is currently a market hotspot, leading to a significant increase in the company's stock price, which rose by 6.52% with trading volume up by 299% compared to the previous day [3][8] - The company is urged to ensure that all disclosures related to this hot topic are accurate and complete to avoid misleading investors [3][8]

Core Viewpoint - Two listed companies, Yahui Long and Tiansheng New Materials, were investigated for information disclosure violations, impacting their stock prices and investor confidence [1][3]. Group 1: Investigation Reasons - Yahui Long's investigation is linked to misleading statements in a recent announcement regarding a strategic cooperation in the "brain-computer interface" sector, which led to a significant stock price increase before a corrective announcement was made [3][4]. - Tiansheng New Materials is under investigation for failing to disclose related party transactions, particularly concerning its financial information from 2023, with ongoing uncertainty about the specifics of the violations [4]. Group 2: Financial Performance and Challenges - Yahui Long reported a significant decline in performance, with a 7.69% drop in revenue to 1.287 billion yuan and a 72.36% decrease in net profit to 60.42 million yuan for the first three quarters of 2025, attributing the downturn to healthcare cost control policies and increased market competition [6][7]. - Tiansheng New Materials faces a more severe situation, with a 16.71% drop in revenue to 334 million yuan and a net loss of 83.12 million yuan for the same period, alongside a negative equity of 30.62 million yuan, risking delisting if the situation does not improve [7]. Group 3: Regulatory Environment - The recent investigations of Yahui Long and Tiansheng New Materials are part of a broader trend, with eight companies being investigated by the regulatory authority since the beginning of 2026, indicating a tightening regulatory environment with a focus on specific disclosure violations [9].

Group 1 - The core issue revolves around misleading statements made by the company regarding its involvement in the brain-computer interface sector, leading to a regulatory investigation by the China Securities Regulatory Commission (CSRC) [1][4] - The company announced a strategic cooperation framework in early January, claiming its partner was engaged in both invasive and non-invasive technologies, which resulted in a 6.52% increase in stock price and a nearly threefold increase in trading volume on the announcement day [1][4] - Following regulatory scrutiny, the company issued a supplementary announcement clarifying that the partner had no invasive technology and was only in the early stages of non-invasive technology development, revealing significant discrepancies in their disclosures [2][4] Group 2 - Prior to the CSRC's investigation, the Shanghai Stock Exchange had already issued a regulatory warning on January 7, highlighting inaccuracies and incompleteness in the company's disclosures [3][5] - The exchange emphasized the need for the company to provide adequate risk warnings regarding the feasibility and uncertainties of the partnership, as the brain-computer interface is a highly scrutinized market area [5] - The company has been ordered to submit a comprehensive rectification report, with all directors and executives required to confirm their signatures, and to conduct a thorough internal compliance review [5]